Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

(2012) Zuqin Nie et al.   CELL

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

(2012) Charles Y. Lin et al.   CELL

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma

(2012) Uma M. Sachdeva et al.   JOURNAL OF CLINICAL INVESTIGATION

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Functional genomics identifies therapeutic targets for MYC-driven cancer

(2012) M. Toyoshima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

C-MYCAlterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

Physiological Relevance of Cell Cycle Kinases

(2011) Marcos Malumbres   PHYSIOLOGICAL REVIEWS

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis

(2011) J. D. Kessler et al.   SCIENCE

Myc proteins as therapeutic targets

(2010) W C Gustafson et al.   ONCOGENE

Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase

(2010) D. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A pathway-based classification of human breast cancer

(2010) M. L. Gatza et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc

(2009) C. E. Caldon et al.   MOLECULAR AND CELLULAR BIOLOGY

Cdk2 suppresses cellular senescence induced by the c-myc oncogene

(2009) Stefano Campaner et al.   NATURE CELL BIOLOGY

Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup

(2009) M. Chehani Alles et al.   PLoS One

Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery

(2009) Jessica Kao et al.   PLoS One

A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response

(2009) Sanjay Chandriani et al.   PLoS One

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

(2009) J. J. Molenaar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer

(2008) Elizabeth A. Musgrove et al.   PLoS One